A Phase 3 interventional study of Mavacamten and Placebo in Obstructive Hypertrophic Cardiomyopathy, sponsored by LianBio LLC. Completed at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by LianBio LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 6 in phase 3, and was the 10th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:
University of Manchester · Sites in United Kingdom
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University
Ages 18+
By country, each count listing its studies:
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 7 · Phase 4 4
First in 2014; this study’s year is marked. 4 started in 2022.
This study's enrollment of 81 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 75 across the 21 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
LianBio LLC is the lead sponsor of 7 studies on the registry; none are open to participants now.
LianBio LLC has 2 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.
This is a randomized, double-blinded, placebo-controlled clinical study witha long-term extension to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM. Approximately 81eligible participants will be enrolled and randomized in a 2:1 ratio (mavacamten:placebo). Participants will receive mavacamten or matching placebofor 30 weeks indouble-blinded manner. After 30-week double-blinded placebo-controlled treatment, eligible participants will receive mavacamten for additional 48 weeks (placebogroup: switch from placebo to mavacamten, mavacamten group: maintain on mavacamten).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mavacamten Capsules
Drug: Mavacamten
Matching Placebo Capsules
Drug: Placebo
Mavacamten Capsules
Also known as: MYK-461, BMS-986327
Matching PBO capsules during placebo controlled period,and mavacamten capsules during long term extension period
Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient
To compare the effect of a 30-week course of mavacamten with placebo on Valsalva LVOT peak gradient as determined by Doppler echocardiography
Time frame: 30 weeks
Change From Baseline to Week 30 in Resting LVOT Peak Gradient
To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.
Time frame: 30 weeks
Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30
To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.
Time frame: 30 weeks
Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30.
To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.
Time frame: 30 weeks
Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30
To compare the effect of a 30-week course of mavacamten with placebo on clinical symptoms
Time frame: 30 weeks
Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
To compare the effect of a 30-week course of Mavacamten with placebo on Participant-Reported health status individually The KCCQ (23-item version) is a patient-reported questionnaire that measures the impact of patients' CV disease or its treatment on 6 distinct domains using a 2-week recall: symptoms/signs, physical limitations, quality of life, social limitations, self-efficacy, and symptom stability (Green et al., 2000). In addition to the individual domains, 2 summary scores can be calculated from the KCCQ: the overall summary score (includes the total symptom, physical limitation, social limitations and quality of life scores) and the clinical summary score (combines the total symptom and physical limitation scales). Scores range from 0 to 100, with higher scores reflecting better health status. The KCCQ will be administered to participants as indicated.
Time frame: 30 weeks
Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)
To compare the effect of a 30-week course of mavacamten on cardiac biomarkers
Time frame: 30 weeks
Change From Baseline to Week 30 in Cardiac Troponin
To compare the effect of a 30-week course of mavacamten on cardiac biomarkers
Time frame: 30 weeks
Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index
To compare the effect of a 30-week course of mavacamten with placebo on LV mass evaluated by cardiac magnetic resonance (CMR) imaging.
Time frame: 30 weeks
| Milestone | Mavacamten | Placebo |
|---|---|---|
| Started | 54 | 27 |
| Completed | 54 | 27 |
| Not completed | 0 | 0 |
To compare the effect of a 30-week course of mavacamten with placebo on Valsalva LVOT peak gradient as determined by Doppler echocardiography
| mmHg | Mavacamten | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient | -51.05 ± 6.150 | 19.23 ± 8.535 |
To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.
| mmHg | Mavacamten | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in Resting LVOT Peak Gradient | -49.04 ± 4.637 | 5.95 ± 6.311 |
To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.
| Participants | Mavacamten | Placebo |
|---|---|---|
| Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 30 mmHg at Week 30 | 26 | 1 |
To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction.
| Participants | Mavacamten | Placebo |
|---|---|---|
| Proportion of Participants Achieving a Valsalva LVOT Peak Gradient < 50 mmHg at Week 30. | 32 | 2 |
To compare the effect of a 30-week course of mavacamten with placebo on clinical symptoms
| Participants | Mavacamten | Placebo |
|---|---|---|
| Proportion of Participants With at Least 1 Class Improvement in New York Heart Association (NYHA) Functional Classification From Baseline to Week 30 | 32 | 4 |
To compare the effect of a 30-week course of Mavacamten with placebo on Participant-Reported health status individually The KCCQ (23-item version) is a patient-reported questionnaire that measures the impact of patients' CV disease or its treatment on 6 distinct domains using a 2-week recall: symptoms/signs, physical limitations, quality of life, social limitations, self-efficacy, and symptom stability (Green et al., 2000). In addition to the individual domains, 2 summary scores can be calculated from the KCCQ: the overall summary score (includes the total symptom, physical limitation, social limitations and quality of life scores) and the clinical summary score (combines the total symptom and physical limitation scales). Scores range from 0 to 100, with higher scores reflecting better health status. The KCCQ will be administered to participants as indicated.
| score on a scale | Mavacamten | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) | 4.99 ± 2.063 | -5.25 ± 2.750 |
To compare the effect of a 30-week course of mavacamten on cardiac biomarkers
| ng/L | Mavacamten | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) | 0.182 ± 0.1743 | 0.932 ± 0.5133 |
To compare the effect of a 30-week course of mavacamten on cardiac biomarkers
| ng/L | Mavacamten | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in Cardiac Troponin | 0.419 ± 0.1983 | 1.236 ± 0.6528 |
To compare the effect of a 30-week course of mavacamten with placebo on LV mass evaluated by cardiac magnetic resonance (CMR) imaging.
| g/m^2 | Mavacamten | Placebo |
|---|---|---|
| Change From Baseline to Week 30 in Left Ventricular (LV) Mass Index | -26.365 ± 21.0565 | 4.434 ± 14.4226 |
Collected over Adverse events were assessed from the first dose date of study medication up to 30 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/27 (0%) | 0/27 (0%) | 24/27 (88.9%) |
| Mavacamten | 0/54 (0%) | 4/54 (7.4%) | 45/54 (83.3%) |
| Event | Placebo | Mavacamten |
|---|---|---|
| HaemorrhoidsGastrointestinal disorders | 0/27 | 1/54 |
| Atrial flutterCardiac disorders | 0/27 | 1/54 |
| fibrillationCardiac disorders | 0/27 | 1/54 |
| HypotensionVascular disorders | 0/27 | 1/54 |
| Ankle fractureInjury, poisoning and procedural complications | 0/27 | 1/54 |
| Sinus arrestCardiac disorders | 0/27 | 1/54 |
| Atrial fibrillationCardiac disorders | 0/27 | 1/54 |
| Event | Placebo | Mavacamten |
|---|---|---|
| COVID-19Infections and infestations | 11/27 | 20/54 |
| Upper respiratory tract infectionInfections and infestations | 4/27 | 8/54 |
| HyperuricemiaMetabolism and nutrition disorders | 2/27 | 7/54 |
| DizzinessNervous system disorders | 2/27 | 7/54 |
| Ventricular extrasystolesCardiac disorders | 3/27 | 2/54 |
| Defect conduction intraventricularCardiac disorders | 0/27 | 5/54 |
| PalpitationsCardiac disorders | 2/27 | 3/54 |
| Ventricular tachycardiaCardiac disorders | 2/27 | 2/54 |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/27 | 4/54 |
| HeadacheNervous system disorders | 2/27 | 1/54 |
| Age, Categorical(Participants) | Mavacamten | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 47 | 23 | 70 |
| >=65 years | 7 | 4 | 11 |
| Age, Continuous(years) | Mavacamten | Placebo | Total |
|---|---|---|---|
| Mean | 52.4 ± 12.08 | 51.0 ± 11.83 | 51.9 ± 11.94 |
| Sex: Female, Male(Participants) | Mavacamten | Placebo | Total |
|---|---|---|---|
| Female | 13 | 10 | 23 |
| Male | 41 | 17 | 58 |
| Ethnicity (NIH/OMB)(Participants) | Mavacamten | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 54 | 27 | 81 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Mavacamten | Placebo | Total |
|---|---|---|---|
| China | 54 | 27 | 81 |
| Valsalva LVOT peak gradient(mmHg) | Mavacamten | Placebo | Total |
|---|---|---|---|
| Mean | 106.78 ± 43.225 | 99.79 ± 41.100 | 104.45 ± 42.401 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Mar 2023, 14 months.
Results were first posted in Sep 2024, 1 year 6 months after primary completion.
Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →
LianBio LLC